SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:lnu-111261"
 

Sökning: onr:"swepub:oai:DiVA.org:lnu-111261" > Trends, geographica...

  • Rocha, João VictorNOVA University Lisbon, Portugal (författare)

Trends, geographical variation and factors associated with the use of anti-VEGF intravitreal injections in Portugal (2013–2018): a retrospective analysis of administrative data

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-04-06
  • BMJ Publishing Group Ltd,2022
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:lnu-111261
  • https://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-111261URI
  • https://doi.org/10.1136/bmjopen-2021-055478DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Title in Swedish: Trender, geografisk variation och faktorer förknippade med användningen av anti-VEGF intravitreala injektioner i Portugal (2013–2018): en retrospektiv analys av administrativa data
  • Aims The arrival of anti-vascular endothelial growth factor (anti-VEGF) therapies represented a treatment shift for several ophthalmological disorders and led to an increasing number of patients undergoing intravitreal injections. The aims of this observational study were to assess the expansion of anti-VEGF intravitreal injections in the Portuguese National Health System (NHS) and to identify factors correlated with geographical variations in episode rates.Methods Administrative database on discharge from Portuguese NHS hospitals was analysed for annual values and rates of intravitreal anti-VEGF injections at a national and regional level, between 2013 and 2018.Results The number of episodes of anti-VEGF treatment and patients treated increased 16% and 9% per year, respectively, between 2013 and 2018. During the study period around 72% of patients were treated in the Metropolitan areas of Lisbon and Porto and in the Central region. Intravitreal anti-VEGF treatment rates in 2018 were 560 per 100 000 population and presented high variability between municipalities. Higher anti-VEGF treatment rates at the municipality level were associated with shorter distances between their residence and the hospital. At the hospital level, higher ratio of ophthalmologists and higher organisational level were associated with higher anti-VEGF treatment rates.Conclusion The number of episodes and patients treated with anti-VEGF injections has been growing in recent years. Proximity to healthcare, more access to ophthalmologists and hospitals with higher organisational levels are associated with higher anti-VEGF treatment rates. Improving access is crucial to reduce regional discrepancies and ensure optimal treatment frequency, which may improve health outcomes.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Marques, Ana PatriciaNOVA University Lisbon, Portugal (författare)
  • Macedo, António Filipe,Senior Lecturer,1976-Linnéuniversitetet,Institutionen för medicin och optometri (MEO),Hållbar hälsa(Swepub:lnu)anmaag (författare)
  • Afonso-Silva, MartaNovartis Farma Produtos Farmacêuticos SA, Portugal (författare)
  • Laires, PedroNOVA University Lisbon, Portugal;Novartis Farma Produtos Farmacêuticos SA, Portugal (författare)
  • Almeida, Ana SofiaNovartis Farma Produtos Farmacêuticos SA, Portugal (författare)
  • Fernandes, JulietaNovartis Farma Produtos Farmacêuticos SA, Portugal (författare)
  • Pardal, MarisaNovartis Farma Produtos Farmacêuticos SA, Portugal (författare)
  • Santana, RuiNOVA University Lisbon, Portugal (författare)
  • NOVA University Lisbon, PortugalInstitutionen för medicin och optometri (MEO) (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:BMJ Open: BMJ Publishing Group Ltd12:42044-6055

Internetlänk

Hitta via bibliotek

  • BMJ Open (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy